通心络胶囊对高血压患者的降压效果观察

Effect of the Tongxinluo capsule on primary hypertension

目的:观察通心络胶囊对原发性高血压的降压效果并探讨可能的作用机理。方法:将60例高血压患者随机配对分为常规(卡托普利)降压治疗组及通心络胶囊治疗组,每组30例;同时收集30例健康人作为对照组。疗程结束后,观察治疗前后血压变化及血浆中内皮素(endothelin,ET)和一氧化氮(nitric oxide,NO)的变化。结果:①治疗后通心络组与常规组血压下降明显(P均<0.05),但二者之间无明显差异(P>0.05);②经通心络治疗后ET明显下降,NO明显升高(P均<0.05),但与常规组和对照组比较无统计学差异(P>0.05)。结论:通心络胶囊具有减少ET和增加NO的作用,是治疗原发性高血压的一种有效的降压药。

Objective： To observe the depressurization effect of the Tongxinluo capsule on primary hypertension. Methods： Sixty patients with primary hypertension were matched-paired and randomly divided into two groups： 30 in the routine group （RG） treated with captopril, and the other 30 in the Tongxinluo group （TG）. At the same time 30 healthy humans were enrolled in the control group （CG）. Blood pressure （BP）, endothelin （ET） and nitric oxide （NO） were determined both before and after the one-month treatment. Results： （1） Both Captopril and the Tongxinluo Capsule had a statistically great depressurization effect（ P 〈 0.05） ; （2） NO was increased and ET was decreased in the TG group （ P 〈 0.05）. There was no significant difference among the three groups after treatment （ P 〉 0.05）. Conclusion： The Tongxinluo capsule can protect the vascular endothelium by reducing ET and increasing NO and it is an effective medicine for primary hypertension.